4 Insights on decentralized trials for biotechs

The COVID-19 pandemic accelerated the adoption of decentralized clinical trials (DCTs) by biopharma companies. The clinician-patient relationship will always be key to clinical trials, but decentralized aspects such as direct-to-patient shipments and telehealth are here to stay. Here are four things we have learned about DCTs that biotech companies can consider when designing a decentralized or hybrid trial.

Open PDF

Return to Insights Center